Last reviewed · How we verify
Edaravone Dexborneol
Edaravone Dexborneol is a combination of a free radical scavenger and a borneol-based neuroprotective agent that reduces oxidative stress and improves cerebral blood flow.
Edaravone Dexborneol is a combination of a free radical scavenger and a borneol-based neuroprotective agent that reduces oxidative stress and improves cerebral blood flow. Used for Acute ischemic stroke.
At a glance
| Generic name | Edaravone Dexborneol |
|---|---|
| Also known as | edaravone deborbeol placebo, Xian Bi Xin placebo |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Free radical scavenger combination |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Edaravone acts as a potent free radical scavenger, particularly targeting hydroxyl radicals and peroxynitrite that accumulate during ischemic stroke. Dexborneol, a monoterpene alcohol, enhances neuroprotection by improving microcirculation and reducing cerebral edema. Together, they work synergistically to limit ischemic damage and promote neurological recovery in acute stroke.
Approved indications
- Acute ischemic stroke
Common side effects
- Headache
- Dizziness
- Nausea
- Injection site reactions
Key clinical trials
- Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study (PHASE4)
- Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease (PHASE3)
- Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients (PHASE2)
- A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy (PHASE4)
- Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke (PHASE4)
- Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol (PHASE4)
- The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS (PHASE3)
- Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Edaravone Dexborneol CI brief — competitive landscape report
- Edaravone Dexborneol updates RSS · CI watch RSS
- First Affiliated Hospital, Sun Yat-Sen University portfolio CI